Eli Lilly Pledges $27 Billion for Six U.S. Plants, Details Four Sites
Eli Lilly plans six U.S. manufacturing plants with at least $27 billion investment to boost domestic production. It has revealed sites in Alabama, Virginia and Texas and in January announced a $3.5 billion plant in Pennsylvania as its fourth U.S. site.
1. U.S. Tariff Threat Spurs Domestic Investment
Facing a potential 100% tariff on imported branded and patented medicines, Eli Lilly has accelerated its U.S. manufacturing strategy, securing delayed enforcement through substantial domestic investment commitments. The company’s pledge of at least $27 billion underscores its effort to strengthen supply chains and avoid future tariff penalties.
2. Details of New U.S. Facilities
Lilly has identified three plant locations in Alabama, Virginia and Texas and, in January, announced a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania as its fourth new U.S. site. The overall plan calls for six domestic plants, aiming to bolster production capacity and resilience in critical drug supply lines.